BlossomHill Therapeutics Inc BLSM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $17.48
- Day Range
- $16.93–17.53
- 52-Week Range
- $15.25–27.99
- Bid/Ask
- $17.32 / $17.92
- Shares Outstanding
- 31.78M
- Market Cap
- $549.56M
- Volume/Avg
- 21,718 / 258,372
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 69
- Website
- https://www.bhtherapeutics.com
Valuation
|
Metric
|
BLSM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BLSM
|
|---|---|
Quick Ratio | 5.12 |
Current Ratio | 5.42 |
Interest Coverage | — |
Quick Ratio
BLSM
Profitability
|
Metric
|
BLSM
|
|---|---|
Return on Assets (Normalized) | −55.81% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BLSM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|sLKN@Y | LOCK|cg#>w | $129B | |||
| Moderna Inc
MRNA
| LOCK|!P>pk# | LOCK|Sr& | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@@#&Xd | LOCK|!tJ?< | $77B | |||
| argenx SE ADR
ARGX
| LOCK|#^^d?j | LOCK|N# | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@H$>Zyd | LOCK|Q? | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$$l@<?$ | LOCK|rM$k# | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%L@s&s< | LOCK|#?cPM | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|G>p<<! | LOCK|D@ | $24B | |||
| Incyte Corp
INCY
| LOCK|R$&$sW | LOCK|J& | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>L@!$L< | LOCK|cS | $14B |
United States